Bioversys announces strategic investment in GIBF2 and launch of BV100 clinical program in China
BASEL, Switzerland, Sept. 11, 2024 (GLOBE NEWSWIRE) — GIBF2 to invest US$6 million in BioVersys The Phase 1 study of BV100 in China is expected to begin in the first half of 2025 in preparation for a global Phase 3 registration study. BioVersys AGa multi-asset, clinical-stage biopharmaceutical company focused on …